Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott David Solomon, M.D.

Co-Author

This page shows the publications co-authored by Scott Solomon and Brian Claggett.
Connection Strength

33.311
  1. Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". Circulation. 2019 01 15; 139(3):422-423.
    View in: PubMed
    Score: 0.797
  2. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. Circulation. 2018 08 07; 138(6):570-577.
    View in: PubMed
    Score: 0.773
  3. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. Eur Heart J. 2022 Mar 23.
    View in: PubMed
    Score: 0.248
  4. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022 Mar; 10(3):184-197.
    View in: PubMed
    Score: 0.247
  5. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail. 2022 Feb 04.
    View in: PubMed
    Score: 0.246
  6. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 Jan 05.
    View in: PubMed
    Score: 0.245
  7. Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. J Card Fail. 2021 Dec 26.
    View in: PubMed
    Score: 0.244
  8. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
    View in: PubMed
    Score: 0.243
  9. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circ Heart Fail. 2021 12; 14(12):e008597.
    View in: PubMed
    Score: 0.243
  10. Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. Clin Transplant. 2022 01; 36(1):e14492.
    View in: PubMed
    Score: 0.240
  11. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.238
  12. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. JACC Heart Fail. 2021 09; 9(9):627-635.
    View in: PubMed
    Score: 0.237
  13. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
    View in: PubMed
    Score: 0.236
  14. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021 07; 23(7):1217-1225.
    View in: PubMed
    Score: 0.235
  15. Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. Eur J Heart Fail. 2021 08; 23(8):1290-1295.
    View in: PubMed
    Score: 0.235
  16. Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. Circulation. 2021 07 13; 144(2):177-179.
    View in: PubMed
    Score: 0.234
  17. Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 09 07; 10(17):e022069.
    View in: PubMed
    Score: 0.234
  18. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). Eur J Heart Fail. 2021 06; 23(6):1052-1056.
    View in: PubMed
    Score: 0.234
  19. Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. J Am Coll Cardiol. 2021 07 06; 78(1):89-91.
    View in: PubMed
    Score: 0.234
  20. Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19. JAMA Intern Med. 2021 May 01; 181(5):714-717.
    View in: PubMed
    Score: 0.234
  21. Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. Int J Cardiol. 2021 07 15; 335:59-65.
    View in: PubMed
    Score: 0.233
  22. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
    View in: PubMed
    Score: 0.231
  23. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. JACC Heart Fail. 2021 05; 9(5):386-397.
    View in: PubMed
    Score: 0.231
  24. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. Eur J Heart Fail. 2021 08; 23(8):1346-1356.
    View in: PubMed
    Score: 0.231
  25. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail. 2021 01; 9(1):65-73.
    View in: PubMed
    Score: 0.228
  26. Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension. 2021 02; 77(2):546-556.
    View in: PubMed
    Score: 0.228
  27. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. Circ Heart Fail. 2020 12; 13(12):e008007.
    View in: PubMed
    Score: 0.226
  28. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC Heart Fail. 2021 01; 9(1):13-24.
    View in: PubMed
    Score: 0.226
  29. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 11; 22(11):2093-2101.
    View in: PubMed
    Score: 0.224
  30. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med. 2020 Sep 09.
    View in: PubMed
    Score: 0.223
  31. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 10; 8(10):844-855.
    View in: PubMed
    Score: 0.223
  32. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020 09 29; 142(13):1236-1245.
    View in: PubMed
    Score: 0.222
  33. Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. JACC Heart Fail. 2020 08; 8(8):698-699.
    View in: PubMed
    Score: 0.222
  34. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail. 2020 10; 8(10):811-818.
    View in: PubMed
    Score: 0.221
  35. Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth. JACC Heart Fail. 2020 07; 8(7):597-598.
    View in: PubMed
    Score: 0.220
  36. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J. 2020 07 01; 41(25):2356-2362.
    View in: PubMed
    Score: 0.220
  37. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. JACC Heart Fail. 2020 08; 8(8):640-653.
    View in: PubMed
    Score: 0.220
  38. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020 07 11; 396(10244):121-128.
    View in: PubMed
    Score: 0.219
  39. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020 09; 22(9):1662-1671.
    View in: PubMed
    Score: 0.218
  40. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 08; 8(8):618-626.
    View in: PubMed
    Score: 0.218
  41. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol. 2020 05 01; 5(5):576-581.
    View in: PubMed
    Score: 0.218
  42. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 05; 8(5):372-381.
    View in: PubMed
    Score: 0.217
  43. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. J Am Coll Cardiol. 2020 04 14; 75(14):1644-1656.
    View in: PubMed
    Score: 0.216
  44. Reply: Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 03; 8(3):245-246.
    View in: PubMed
    Score: 0.215
  45. How Do SGLT-2 Inhibitors Work to Prevent Heart Failure? JACC Heart Fail. 2020 01; 8(1):67-69.
    View in: PubMed
    Score: 0.213
  46. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020 02 04; 141(5):338-351.
    View in: PubMed
    Score: 0.211
  47. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.211
  48. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020 01 28; 75(3):245-254.
    View in: PubMed
    Score: 0.211
  49. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
    View in: PubMed
    Score: 0.209
  50. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
    View in: PubMed
    Score: 0.208
  51. The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2019 10; 21(10):1207-1215.
    View in: PubMed
    Score: 0.207
  52. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2019 10; 21(10):1288-1291.
    View in: PubMed
    Score: 0.206
  53. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2019 08; 7(8):664-675.
    View in: PubMed
    Score: 0.206
  54. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 07; 12(7):e006125.
    View in: PubMed
    Score: 0.205
  55. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. JAMA Cardiol. 2019 05 01; 4(5):466-472.
    View in: PubMed
    Score: 0.203
  56. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.201
  57. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
    View in: PubMed
    Score: 0.200
  58. HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. Hypertension. 2019 01; 73(1):68-74.
    View in: PubMed
    Score: 0.199
  59. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2018 11; 11(11):e005288.
    View in: PubMed
    Score: 0.196
  60. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. J Am Coll Cardiol. 2018 10 09; 72(15):1763-1773.
    View in: PubMed
    Score: 0.196
  61. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018 10 01; 3(10):1000-1005.
    View in: PubMed
    Score: 0.195
  62. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018 10; 11(10):e005133.
    View in: PubMed
    Score: 0.195
  63. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. 2018 09; 3(9):e419-e428.
    View in: PubMed
    Score: 0.194
  64. Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. Stat Med. 2018 11 10; 37(25):3589-3598.
    View in: PubMed
    Score: 0.193
  65. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. JACC Heart Fail. 2018 08; 6(8):689-697.
    View in: PubMed
    Score: 0.192
  66. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.
    View in: PubMed
    Score: 0.191
  67. Adiposity, body composition and ventricular-arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study. Eur J Heart Fail. 2018 08; 20(8):1191-1201.
    View in: PubMed
    Score: 0.189
  68. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
    View in: PubMed
    Score: 0.189
  69. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. Am J Hypertens. 2018 03 10; 31(4):407-414.
    View in: PubMed
    Score: 0.188
  70. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. JACC Heart Fail. 2018 08; 6(8):653-661.
    View in: PubMed
    Score: 0.188
  71. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC Heart Fail. 2018 07; 6(7):564-569.
    View in: PubMed
    Score: 0.188
  72. Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2018 03 01; 3(3):200-206.
    View in: PubMed
    Score: 0.187
  73. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 08; 20(8):1230-1239.
    View in: PubMed
    Score: 0.187
  74. Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance. Circ Heart Fail. 2017 Dec; 10(12).
    View in: PubMed
    Score: 0.184
  75. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail. 2018 03; 20(3):504-510.
    View in: PubMed
    Score: 0.184
  76. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. Eur J Heart Fail. 2018 03; 20(3):483-490.
    View in: PubMed
    Score: 0.184
  77. Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. Eur J Heart Fail. 2018 04; 20(4):815-816.
    View in: PubMed
    Score: 0.183
  78. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. JACC Heart Fail. 2017 11; 5(11):782-791.
    View in: PubMed
    Score: 0.183
  79. Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Oct 01; 18(10):1128-1137.
    View in: PubMed
    Score: 0.182
  80. Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. Eur J Heart Fail. 2018 07; 20(7):1106-1114.
    View in: PubMed
    Score: 0.181
  81. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation. 2017 Sep 12; 136(11):982-992.
    View in: PubMed
    Score: 0.179
  82. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. JACC Heart Fail. 2017 04; 5(4):241-252.
    View in: PubMed
    Score: 0.176
  83. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J Am Heart Assoc. 2017 Mar 24; 6(4).
    View in: PubMed
    Score: 0.176
  84. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
    View in: PubMed
    Score: 0.176
  85. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.
    View in: PubMed
    Score: 0.173
  86. Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. JACC Heart Fail. 2017 03; 5(3):157-165.
    View in: PubMed
    Score: 0.173
  87. Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study. Eur J Heart Fail. 2017 03; 19(3):340-347.
    View in: PubMed
    Score: 0.172
  88. Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study. Circulation. 2017 01 31; 135(5):426-439.
    View in: PubMed
    Score: 0.172
  89. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 06; 68(22):2425-2436.
    View in: PubMed
    Score: 0.172
  90. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.172
  91. Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation. 2017 Jan 17; 135(3):224-240.
    View in: PubMed
    Score: 0.172
  92. Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. Circulation. 2016 Nov 01; 134(18):1328-1338.
    View in: PubMed
    Score: 0.170
  93. Smoking and Cardiac Structure and Function in the Elderly: The ARIC Study (Atherosclerosis Risk in Communities). Circ Cardiovasc Imaging. 2016 Sep; 9(9):e004950.
    View in: PubMed
    Score: 0.169
  94. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016 09 01; 1(6):666-72.
    View in: PubMed
    Score: 0.169
  95. Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). Circ Heart Fail. 2016 08; 9(8).
    View in: PubMed
    Score: 0.168
  96. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.167
  97. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur J Heart Fail. 2016 Oct; 18(10):1238-1243.
    View in: PubMed
    Score: 0.167
  98. Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study. Eur Heart J. 2016 Aug 21; 37(32):2544-51.
    View in: PubMed
    Score: 0.165
  99. Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2016 06; 18(6):629-37.
    View in: PubMed
    Score: 0.164
  100. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.163
  101. Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly: The Atherosclerosis Risk in Communities Study. Circ Cardiovasc Imaging. 2016 Feb; 9(2):e004010.
    View in: PubMed
    Score: 0.162
  102. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016 May; 39(5):677-85.
    View in: PubMed
    Score: 0.162
  103. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med. 2015 Dec 03; 373(23):2289-90.
    View in: PubMed
    Score: 0.161
  104. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circ Heart Fail. 2015 Nov; 8(6):1052-8.
    View in: PubMed
    Score: 0.159
  105. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016 Feb 01; 37(5):455-62.
    View in: PubMed
    Score: 0.158
  106. Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation. 2015 Nov 24; 132(21):1979-89.
    View in: PubMed
    Score: 0.158
  107. Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study. Am J Hypertens. 2016 May; 29(5):568-74.
    View in: PubMed
    Score: 0.158
  108. Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”. Circ Heart Fail. 2015 Sep; 8(5):1010.
    View in: PubMed
    Score: 0.158
  109. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation. 2015 Aug 04; 132(5):402-14.
    View in: PubMed
    Score: 0.156
  110. Relationship between alcohol consumption and cardiac structure and function in the elderly: the Atherosclerosis Risk In Communities Study. Circ Cardiovasc Imaging. 2015 Jun; 8(6).
    View in: PubMed
    Score: 0.155
  111. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 07; 36(30):1990-7.
    View in: PubMed
    Score: 0.155
  112. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc. 2015 May 21; 4(5).
    View in: PubMed
    Score: 0.155
  113. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
    View in: PubMed
    Score: 0.154
  114. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. Circ Heart Fail. 2015 May; 8(3):448-54.
    View in: PubMed
    Score: 0.153
  115. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2015 Mar; 17(3):301-12.
    View in: PubMed
    Score: 0.152
  116. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. Eur Heart J. 2015 Apr 14; 36(15):939-45.
    View in: PubMed
    Score: 0.151
  117. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015 Jan 01; 372(1):21-9.
    View in: PubMed
    Score: 0.151
  118. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. Eur Heart J. 2015 Mar 14; 36(11):669-75.
    View in: PubMed
    Score: 0.149
  119. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circ Heart Fail. 2014 Nov; 7(6):895-902.
    View in: PubMed
    Score: 0.148
  120. Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). JACC Heart Fail. 2014 Oct; 2(5):447-54.
    View in: PubMed
    Score: 0.147
  121. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.147
  122. Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation. 2014 Sep 02; 130(10):820-8.
    View in: PubMed
    Score: 0.147
  123. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail. 2014 Jul; 7(4):590-5.
    View in: PubMed
    Score: 0.145
  124. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014 Jun; 16(6):671-7.
    View in: PubMed
    Score: 0.143
  125. Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. J Hypertens. 2014 Jan; 32(1):174-80.
    View in: PubMed
    Score: 0.141
  126. Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). JACC Heart Fail. 2013 Dec; 1(6):531-6.
    View in: PubMed
    Score: 0.140
  127. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014 Jan; 35(1):42-7.
    View in: PubMed
    Score: 0.139
  128. Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. Hypertension. 2013 Sep; 62(3):492-8.
    View in: PubMed
    Score: 0.136
  129. Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review. JAMA Cardiol. 2022 Apr 01; 7(4):450-456.
    View in: PubMed
    Score: 0.062
  130. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation. 2022 Mar 31.
    View in: PubMed
    Score: 0.062
  131. Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults. J Am Heart Assoc. 2022 03 15; 11(6):e022308.
    View in: PubMed
    Score: 0.062
  132. Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study. J Am Heart Assoc. 2022 03 15; 11(6):e021715.
    View in: PubMed
    Score: 0.062
  133. Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. J Am Coll Cardiol. 2022 02 01; 79(4):355-368.
    View in: PubMed
    Score: 0.062
  134. Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas. Int J Cardiol. 2022 Apr 01; 352:78-83.
    View in: PubMed
    Score: 0.062
  135. Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 Jan 26.
    View in: PubMed
    Score: 0.061
  136. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF. JACC Heart Fail. 2022 Feb; 10(2):119-128.
    View in: PubMed
    Score: 0.061
  137. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022 Mar; 24(3):497-509.
    View in: PubMed
    Score: 0.061
  138. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):26-34.
    View in: PubMed
    Score: 0.061
  139. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec; 6(12):935-945.
    View in: PubMed
    Score: 0.061
  140. Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. Eur J Heart Fail. 2022 02; 24(2):378-384.
    View in: PubMed
    Score: 0.061
  141. Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. J Am Heart Assoc. 2021 12 07; 10(23):e020094.
    View in: PubMed
    Score: 0.061
  142. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021 12 07; 10(23):e021494.
    View in: PubMed
    Score: 0.061
  143. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022 01 04; 145(1):87-89.
    View in: PubMed
    Score: 0.061
  144. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 11 11; 385(20):1845-1855.
    View in: PubMed
    Score: 0.061
  145. Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. Clin Res Cardiol. 2022 Apr; 111(4):451-459.
    View in: PubMed
    Score: 0.061
  146. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 11 01; 6(11):1298-1305.
    View in: PubMed
    Score: 0.060
  147. A-lines and B-lines in patients with acute heart failure. Eur Heart J Acute Cardiovasc Care. 2021 Oct 27; 10(8):909-917.
    View in: PubMed
    Score: 0.060
  148. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2021 11; 14(11):e008293.
    View in: PubMed
    Score: 0.060
  149. Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study. J Clin Hypertens (Greenwich). 2021 10; 23(10):1887-1896.
    View in: PubMed
    Score: 0.060
  150. Associations of Insulin Resistance With Systolic and Diastolic Blood Pressure: A Study From the HCHS/SOL. Hypertension. 2021 09; 78(3):716-725.
    View in: PubMed
    Score: 0.060
  151. Heart failure associated with imported malaria: a nationwide Danish cohort study. ESC Heart Fail. 2021 10; 8(5):3521-3529.
    View in: PubMed
    Score: 0.059
  152. Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. J Card Fail. 2021 12; 27(12):1382-1392.
    View in: PubMed
    Score: 0.059
  153. Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. Eur J Heart Fail. 2021 12; 23(12):2085-2090.
    View in: PubMed
    Score: 0.059
  154. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.
    View in: PubMed
    Score: 0.059
  155. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug; 110(8):1334-1349.
    View in: PubMed
    Score: 0.059
  156. Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. J Gen Intern Med. 2021 08; 36(8):2532-2535.
    View in: PubMed
    Score: 0.059
  157. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021 07 13; 78(2):97-108.
    View in: PubMed
    Score: 0.059
  158. Specific Electrocardiograph Intervals Predict Hospitalization with Atrial Fibrillation in Those with Chronic Kidney Disease. Am J Nephrol. 2021; 52(5):412-419.
    View in: PubMed
    Score: 0.058
  159. Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. JAMA Cardiol. 2021 05 01; 6(5):509-520.
    View in: PubMed
    Score: 0.058
  160. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021 06; 23(6):1040-1048.
    View in: PubMed
    Score: 0.058
  161. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circ Heart Fail. 2021 04; 14(4):e007901.
    View in: PubMed
    Score: 0.058
  162. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2021 05; 9(5):374-382.
    View in: PubMed
    Score: 0.058
  163. Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Fail. 2021 06; 8(3):1784-1795.
    View in: PubMed
    Score: 0.058
  164. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
    View in: PubMed
    Score: 0.058
  165. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021 05; 23(5):776-784.
    View in: PubMed
    Score: 0.058
  166. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. Circ Heart Fail. 2021 03; 14(3):e007891.
    View in: PubMed
    Score: 0.058
  167. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Fail. 2021 04; 8(2):1130-1138.
    View in: PubMed
    Score: 0.057
  168. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021 01 05; 325(1):39-49.
    View in: PubMed
    Score: 0.057
  169. Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF. J Am Coll Cardiol. 2020 11 17; 76(20):2417-2418.
    View in: PubMed
    Score: 0.057
  170. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2021 01; 9(1):42-51.
    View in: PubMed
    Score: 0.057
  171. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation. 2020 11 24; 142(21):2080-2082.
    View in: PubMed
    Score: 0.056
  172. Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. PLoS Med. 2020 10; 17(10):e1003361.
    View in: PubMed
    Score: 0.056
  173. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovasc Diabetol. 2020 10 12; 19(1):175.
    View in: PubMed
    Score: 0.056
  174. Estimating the Lifetime Benefits of Treatments for Heart Failure. JACC Heart Fail. 2020 12; 8(12):984-995.
    View in: PubMed
    Score: 0.056
  175. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. J Am Heart Assoc. 2020 10 20; 9(19):e017462.
    View in: PubMed
    Score: 0.056
  176. Associations Between Depressive Symptoms and HFpEF-Related Outcomes. JACC Heart Fail. 2020 12; 8(12):1009-1020.
    View in: PubMed
    Score: 0.056
  177. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 08 04; 76(5):503-514.
    View in: PubMed
    Score: 0.055
  178. Pre-existing traits associated with Covid-19 illness severity. PLoS One. 2020; 15(7):e0236240.
    View in: PubMed
    Score: 0.055
  179. Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2020 09; 43(9):2226-2233.
    View in: PubMed
    Score: 0.055
  180. Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. Eur J Heart Fail. 2020 09; 22(9):1615-1624.
    View in: PubMed
    Score: 0.055
  181. Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. Hypertension. 2020 09; 76(3):808-818.
    View in: PubMed
    Score: 0.055
  182. Use of the Win Ratio in Cardiovascular Trials. JACC Heart Fail. 2020 06; 8(6):441-450.
    View in: PubMed
    Score: 0.055
  183. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 Jul 21; 76(3):280-288.
    View in: PubMed
    Score: 0.055
  184. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020 04 01; 5(4):432-441.
    View in: PubMed
    Score: 0.054
  185. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. Eur J Heart Fail. 2020 07; 22(7):1133-1143.
    View in: PubMed
    Score: 0.054
  186. Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. ESC Heart Fail. 2020 06; 7(3):1201-1209.
    View in: PubMed
    Score: 0.054
  187. Quantification of pleural effusions on thoracic ultrasound in acute heart failure. Eur Heart J Acute Cardiovasc Care. 2020 Aug; 9(5):513-521.
    View in: PubMed
    Score: 0.053
  188. Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. Contemp Clin Trials. 2020 03; 90:105937.
    View in: PubMed
    Score: 0.053
  189. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Circ Heart Fail. 2020 01; 13(1):e006638.
    View in: PubMed
    Score: 0.053
  190. Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. Europace. 2020 01 01; 22(1):74-83.
    View in: PubMed
    Score: 0.053
  191. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.053
  192. Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. Circulation. 2019 12 10; 140(24):2044-2046.
    View in: PubMed
    Score: 0.053
  193. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. JACC Heart Fail. 2019 12; 7(12):1022-1028.
    View in: PubMed
    Score: 0.053
  194. Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2019 12 01; 4(12):1203-1212.
    View in: PubMed
    Score: 0.053
  195. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Eur J Heart Fail. 2019 12; 21(12):1571-1579.
    View in: PubMed
    Score: 0.053
  196. Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2020 03; 22(3):557-559.
    View in: PubMed
    Score: 0.053
  197. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiol. 2019 10 01; 4(10):997-1006.
    View in: PubMed
    Score: 0.052
  198. Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. JACC Heart Fail. 2019 10; 7(10):849-858.
    View in: PubMed
    Score: 0.052
  199. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019 Sep 17; 322(11):1077-1084.
    View in: PubMed
    Score: 0.052
  200. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
    View in: PubMed
    Score: 0.052
  201. Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study. JAMA Netw Open. 2019 06 05; 2(6):e195321.
    View in: PubMed
    Score: 0.051
  202. Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2019 04 01; 4(4):363-369.
    View in: PubMed
    Score: 0.051
  203. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
    View in: PubMed
    Score: 0.050
  204. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.
    View in: PubMed
    Score: 0.050
  205. Influenza Vaccine in Heart Failure. Circulation. 2019 01 29; 139(5):575-586.
    View in: PubMed
    Score: 0.050
  206. Refining Prediction of Atrial Fibrillation-Related Stroke Using the P2-CHA2DS2-VASc Score. Circulation. 2019 01 08; 139(2):180-191.
    View in: PubMed
    Score: 0.050
  207. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. JACC Heart Fail. 2019 01; 7(1):25-32.
    View in: PubMed
    Score: 0.050
  208. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.050
  209. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. J Diabetes Res. 2018; 2018:1631263.
    View in: PubMed
    Score: 0.050
  210. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.049
  211. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circ Heart Fail. 2018 11; 11(11):e005312.
    View in: PubMed
    Score: 0.049
  212. Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. Eur J Heart Fail. 2019 01; 21(1):74-85.
    View in: PubMed
    Score: 0.049
  213. Right Ventricular Function, Right Ventricular-Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiol. 2018 10 01; 3(10):939-948.
    View in: PubMed
    Score: 0.049
  214. The frailty syndrome and outcomes in the TOPCAT trial. Eur J Heart Fail. 2018 11; 20(11):1570-1577.
    View in: PubMed
    Score: 0.049
  215. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 12; 20(12):1701-1709.
    View in: PubMed
    Score: 0.049
  216. Declining Lung Function and Cardiovascular Risk: The ARIC Study. J Am Coll Cardiol. 2018 09 04; 72(10):1109-1122.
    View in: PubMed
    Score: 0.049
  217. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 05; 11(5):e004446.
    View in: PubMed
    Score: 0.047
  218. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
    View in: PubMed
    Score: 0.047
  219. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 06; 6(6):489-498.
    View in: PubMed
    Score: 0.047
  220. Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. JAMA Cardiol. 2018 04 01; 3(4):357-358.
    View in: PubMed
    Score: 0.047
  221. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. J Card Fail. 2018 May; 24(5):313-320.
    View in: PubMed
    Score: 0.047
  222. Widening Racial Differences in Risks for Coronary Heart Disease. Circulation. 2018 03 13; 137(11):1195-1197.
    View in: PubMed
    Score: 0.047
  223. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circ Heart Fail. 2018 03; 11(3):e004457.
    View in: PubMed
    Score: 0.047
  224. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.047
  225. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
    View in: PubMed
    Score: 0.046
  226. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia. 2018 03; 61(3):581-588.
    View in: PubMed
    Score: 0.046
  227. Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation. 2017 10 17; 136(16):1560-1562.
    View in: PubMed
    Score: 0.046
  228. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail. 2018 02; 20(2):295-303.
    View in: PubMed
    Score: 0.045
  229. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.045
  230. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017 07 06; 377(1):41-51.
    View in: PubMed
    Score: 0.045
  231. Sacubitril/valsartan in PARADIGM-HF - Authors' reply. Lancet Diabetes Endocrinol. 2017 07; 5(7):496.
    View in: PubMed
    Score: 0.045
  232. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
    View in: PubMed
    Score: 0.045
  233. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. J Am Heart Assoc. 2017 May 29; 6(6).
    View in: PubMed
    Score: 0.044
  234. Racial Disparities in Risks of Stroke. N Engl J Med. 2017 05 25; 376(21):2089-2090.
    View in: PubMed
    Score: 0.044
  235. Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med. 2017 04 27; 376(17):1690-1692.
    View in: PubMed
    Score: 0.044
  236. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail. 2017 08; 19(8):1043-1052.
    View in: PubMed
    Score: 0.044
  237. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017 Mar 07; 38(10):742-750.
    View in: PubMed
    Score: 0.044
  238. Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). Circ Cardiovasc Imaging. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.043
  239. B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients. Transplantation. 2017 Jan; 101(1):182-190.
    View in: PubMed
    Score: 0.043
  240. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799.
    View in: PubMed
    Score: 0.043
  241. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881.
    View in: PubMed
    Score: 0.042
  242. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
    View in: PubMed
    Score: 0.042
  243. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
    View in: PubMed
    Score: 0.042
  244. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.042
  245. Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). J Am Heart Assoc. 2016 04 23; 5(4).
    View in: PubMed
    Score: 0.041
  246. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr. 2016 06; 29(6):537-44.
    View in: PubMed
    Score: 0.041
  247. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.041
  248. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail. 2016 Mar; 9(3):e001937.
    View in: PubMed
    Score: 0.041
  249. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.040
  250. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Feb; 4(2):152-158.
    View in: PubMed
    Score: 0.040
  251. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 03; 373(23):2247-57.
    View in: PubMed
    Score: 0.040
  252. Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. Eur Heart J. 2016 Feb 01; 37(5):466-72.
    View in: PubMed
    Score: 0.040
  253. Right Atrial Function in Pulmonary Arterial Hypertension. Circ Cardiovasc Imaging. 2015 Nov; 8(11):e003521; discussion e003521.
    View in: PubMed
    Score: 0.040
  254. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 2015 Oct 06; 132(14):1329-37.
    View in: PubMed
    Score: 0.039
  255. On the restricted mean survival time curve in survival analysis. Biometrics. 2016 Mar; 72(1):215-21.
    View in: PubMed
    Score: 0.039
  256. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015 Jul 21; 163(2):127-34.
    View in: PubMed
    Score: 0.039
  257. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. Eur Heart J. 2015 Sep 21; 36(36):2463-9.
    View in: PubMed
    Score: 0.039
  258. Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. Am Heart J. 2015 Aug; 170(2):322-9.
    View in: PubMed
    Score: 0.039
  259. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J Hum Hypertens. 2016 Jan; 30(1):46-52.
    View in: PubMed
    Score: 0.038
  260. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015 May; 169(5):631-638.e7.
    View in: PubMed
    Score: 0.038
  261. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015 May; 17(5):510-7.
    View in: PubMed
    Score: 0.038
  262. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015 Jan 06; 131(1):34-42.
    View in: PubMed
    Score: 0.037
  263. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. Eur J Heart Fail. 2015 Jan; 17(1):63-73.
    View in: PubMed
    Score: 0.037
  264. Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? J Am Coll Cardiol. 2014 Oct 07; 64(14):1535-6.
    View in: PubMed
    Score: 0.037
  265. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014 Nov; 7(6):953-9.
    View in: PubMed
    Score: 0.037
  266. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct; 16(10):1096-103.
    View in: PubMed
    Score: 0.037
  267. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014 Dec 21; 35(48):3442-51.
    View in: PubMed
    Score: 0.036
  268. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014 Aug 01; 32(22):2380-5.
    View in: PubMed
    Score: 0.036
  269. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014 Jul; 7(4):573-9.
    View in: PubMed
    Score: 0.036
  270. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10; 370(15):1383-92.
    View in: PubMed
    Score: 0.036
  271. Reply from the authors. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):869-70.
    View in: PubMed
    Score: 0.036
  272. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 May; 16(5):535-42.
    View in: PubMed
    Score: 0.035
  273. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. J Heart Lung Transplant. 2014 Apr; 33(4):372-81.
    View in: PubMed
    Score: 0.035
  274. Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med. 2013 Dec 15; 188(12):1460-5.
    View in: PubMed
    Score: 0.035
  275. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Feb 11; 63(5):447-56.
    View in: PubMed
    Score: 0.035
  276. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail. 2013 Sep 01; 6(5):970-6.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.